The Business Research Company’s Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth And Change To 2030
LONDON, GREATER LONDON , UK, July 8, 2021 /EINPresswire.com/ — Manufacturers of antibody drug conjugates are increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For instance, in March 2019, Astrazeneca entered into a global development and commercialization collaboration agreement with Daiichi Sankyo Company for the proprietary antibody drug conjugate trastuzumab deruxtecan (DS-8201). In April 2019, Shanghai Miracogen entered into an agreement with Netherlands based Synaffix to use its tools for building antibody drug conjugates. According to the deal, Miracogen is licensing two platforms from Synaffix which is expected to boost its product pipeline.
The antibody-drug conjugates (ADCs) market consists of sales of antibody-drug conjugates. ADCs are complex engineered therapeutics consisting of monoclonal antibodies, directed toward tumor-associated antigens, to which highly potent cytotoxic agents are attached using chemical linkers.
Read More On The Global Antibody Drug Conjugates Market Report:
The global antibody drug conjugates market size is expected to grow from $2.34 billion in 2020 to $2.6 billion in 2021 at a compound annual growth rate (CAGR) of 11.1%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The antibody-drug conjugates (ADCs) market is expected to reach $6.12 billion in 2025 at a CAGR of 23.9%.
Major players in the antibody-drug conjugates (ADCs) industry are Bayer AG, Concortis Biotherapeutics, F. Hoffman-La Roche Ltd., Immunomedics Inc., and Oxford BioTherapeutics.
TBRC’s antibody drug conjugates market report is segmented by type into monoclonal antibodies, linker, drug/toxin, others. The ADCs market is also segmented by application into blood cancer, breast cancer, ovarian cancer, lung cancer, brain tumor, others; by product into adcertis, kadcyla, others; by technology into immunogen technology, seattle genetics technology, immunomedics technology, others; by end user into hospital, clinics, others.
Antibody Drug Conjugates Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides antibody drug conjugates market overview, forecast antibody drug conjugates market size and growth for the whole market, antibody drug conjugates market segments, and geographies, antibody drug conjugates market trends, antibody drug conjugates market drivers, restraints, leading competitors’ revenues, profiles, and market shares.
Request For A Sample Of The Global Antibody Drug Conjugates Market Report:
Here Is A List Of Similar Reports By The Business Research Company:
Monoclonal Antibodies (MAbs) Global Market Report 2021: COVID-19 Impact and Recovery to 2030
Immunosuppressants Global Market Report 2021: COVID-19 Growth And Change To 2030
Molecular Diagnostics Devices And Equipment Global Market Report 2021: COVID-19 Implications And Growth to 2030
Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx
The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.
Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293